FDA’s Proposed Rule Seeks to Restrict Drug Compounding, Group Claims

The FDA’s push to add three additional categories to its 503A list of demonstrably-difficult-to-compound (DDC) drugs is a thinly veiled effort to further restrict compounding in general, the National Community Pharmacists Association (NCPA) said in a comment opposing the proposal.
Source: Drug Industry Daily